Monosodium glutamate as a potential trigger for atrial fibrillatio
- Conditions
- AFatrialfibrillation10007521
- Registration Number
- NL-OMON34775
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 25
Reported monosodiumglutamate triggered atrial fibrillation
Age is between 18 and 80 years
AF is symptomatic and paroxysmal
AF was documented on ECG, Holter or pacemaker electrogram at least once in the 6 months preceding presentation
In sinus rhythm at the moment of study inclusion
Legally competent and willing and able to sign informed consent
Willing and able to adhere to the follow up visit protocol
Myocardial infarction (defined as CKMB> twice upper limit of normal) within the preceding 2 months
NYHA class IV/IV heart failure symptoms, or class II-III with a recent decompensation requiring hospitalization (unless related to or aggravated by AF)
Cerebrovascular accident (defined as any sudden neurological deficit lasting longer than 24 hours, with or without pathological changes on the CT cerebrum) with the preceding 6 months
Known and documented carotid stenosis>80%
Pregnancy or of childbearing potential without adequate contraception
Requirement of antiarrhythmic medication for ventricular arrhythmias
Left ventricular ejection fraction<30%
Severely enlarged left atrium: left atrial volume index>40 ml/m2 or left atrial diameter>52 mm
History of previous radiation therapy on the thorax
Circumstances that prevent follow-up (no permanent home or address, transient, etc.)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint of this study will be AF, confirmed by Holter or 12-lead<br /><br>ECG. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints are two or more symptoms of the MSG symptom complex.</p><br>